BioClinica Announces eHealth App xChange
NEWTOWN, Pa., Sept. 2, 2015 – BioClinica®, Inc., a specialty clinical trials technology and services provider today announced the creation of the eHealth App xChangeTM, an alliance channel for disruptive technology innovation across life sciences and healthcare. BioClinica’s eHealth App xChange provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
The App xChange is a key component of the expanding BioClinica Partner Alliance program, a strategic priority led by eClinical President Mukhtar Ahmed. “BioClinica has a culture of innovation within clinical research,” said Ahmed. “BioClinica’s eHealth App xChange enables research communities to leverage an ecosystem of integrated mobile and cloud applications for unique patient and consumer engagement, digital medicine, biosensor and scientific analytic capabilities, thereby accelerating pre- and post-approval research while creating efficiency and quality benefits.”
Ahmed explained, “Our approach introduces pragmatic industry innovation and provides our customers with an integrated and highly interoperable platform that extends across the entire healthcare research landscape.”
BioClinica Global Product Development Senior Vice President Andrew Masters said, “Healthcare research applications like these are a natural fit with our core products and extend the BioClinica platform with source data capture, point of care, electronic patient record, workflow and safety offerings.” Masters added, “Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, and we welcome new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
